Skip to main content
SpringerLink
Log in

Insulin degludec reduces risk of severe hypoglycaemia

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • PRATLEY RE, et al. Cardiovascular (CV) Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs. Insulin Glargine U100 in Older Patients (≥65 Years) with Type 2 Diabetes (T2D) - Observations from DEVOTE 78th Annual Scientific Sessions of the American Diabetes Association : abstr. 108-OR, 22 Jun 2018. Available from: URL: https://plan.core-apps.com/tristar_ada18/abstract/807d2f9885450670bb994661e361a8c0.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Insulin degludec reduces risk of severe hypoglycaemia. Reactions Weekly 1710, 7 (2018). https://doi.org/10.1007/s40278-018-48681-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-48681-y

Search

Navigation